



DETAILED ADVANCE PROGRAMME

Wednesday 12 March 2014

Satellite Symposium: TBC

10:30 - 12:30

Auditorium

Welcome and Introduction

12:45 - 13:00

Auditorium

Plenary session: Opening Plenary Session

13:00 - 15:30

Auditorium

- Chair: H. Zwierzina (Austria)
 Chair: V. Nussler (Germany)
- 13:00 **KEYNOTE LECTURE: Cancer immunotherapy-current and future advancements**
 Speaker: A.M.M. Eggermont (France)
- 13:30 **KEYNOTE LECTURE: The molecular basis of the immunoediting model**
 Speaker: TBC
- 14:00 **Molecular profiling to identify tumour resistance mechanisms in the microenvironment**
 Speaker: T. Gajewski (USA)
- 14:20 **Toll like receptor 7 agonists for cancer immunotherapy**
 Speaker: S. Endres (Germany)
- 14:40 **Proffered papers**

Coffee Break and Poster session

15:30 - 16:00

Foyer

Plenary session: Cancer immunology

16:00 - 18:00

Auditorium

- Chair: T. Gajewski (USA)
 Chair: P. Romero (Switzerland)
- 16:00 **KEYNOTE LECTURE: Angiogenesis and the immune system**
 Speaker: TBC
- 16:30 **Bavituximab: A Novel Phosphatidylserine-Targeting Immunotherapy for the Treatment of Cancer**
 Speaker: J. Shan (USA)
- 16:50 **KEYNOTE LECTURE: Immunobiological Properties of the Human Cancer Stem Cells**
 Speaker: C. Maccalli (Italy)
- 17:20 **Proffered papers**

Networking Reception

18:00 - 19:30

Foyer



Thursday 13 March 2014

Plenary session: Targeting immune suppression

8:30 - 10:00

Auditorium

- Chair: J.P. Allison, (USA)
Chair: S. Khleif (USA)
- 8:30 **KEYNOTE LECTURE: Regulatory T cells and suppression of immune response**
Speaker: J.P. Allison, (USA)
- 9:00 **Targeting the programmed cell death (PD-1) pathway- from bench to bedside**
Speaker: TBC
- 9:20 **Anti-CTLA4 therapy in combination with targeting the ICOS/ICOSL pathway**
Speaker: P. Sharma (USA)
- 9:40 **Inhibition of indoleamine-2,3-dioxygenase (IDO)- mediated tumour immune escape**
Speaker: C. Opitz (Germany)

Coffee Break

10:00 - 10:30

Foyer

Plenary session: Stimulation of immune function

10:30 - 12:30

Auditorium

- Chair: L. Zitvogel (France)
Chair: A. Dalgleish (United Kingdom)
- 10:30 **Rationales for combining immunotherapy with chemotherapy**
Speaker: A. Dalgleish (United Kingdom)
- 10:50 **Role of gut microbiota in the anticancer effects of cytotoxic drugs**
Speaker: L. Zitvogel (France)
- 11:10 **Oncolytic herpes simplex virus encoding GM-CSF for melanoma therapy**
Speaker: TBC
- 11:30 **Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer**
Speaker: C. Klein (Switzerland)
- 11:50 **Proffered papers**

Lunch and Poster Session

12:30 - 14:00

Foyer

Satellite Symposium: TBC

13:00 - 14:00

Auditorium



Plenary session: Therapeutic anti-cancer vaccines

14:00 - 16:00

Auditorium

- Chair: J.P. Allison (USA)
 Chair: TBC
- 14:00 **KEYNOTE LECTURE- Vaccine Development**
 Speaker: TBC
- 14:30 **Dendritic cell vaccination combined with CTLA4 blockade**
 Speaker: TBC
- 14:50 **Role of CD40 activation in anti-tumour vaccine efficacy**
 Speaker: TBC
- 15:10 **mRNA-based cancer vaccines**
 Speaker: TBC
- 15:30 **Proffered papers**

Plenary session: Monitoring of immunotherapy

16:30 - 18:00

Auditorium

- Chair: L. Hakansson (Sweden)
 Chair: B. Fox (USA)
- 16:30 **Immune response parameters**
 Speaker: L. Hakansson (Sweden)
- 17:00 **Tumour infiltrating lymphocytes- a predictive marker?**
 Speaker: J. Galon (France)
- 17:20 **Biomarker development for Ipilimumab and Prostate GVAX treatment**
 Speaker: T. De Grujil (Netherlands)
- 17:40 **Using genomics to guide cancer immunotherapy**

Satellite Symposium: TBC

18:15 – 19:45

Auditorium

Friday 14 March 2014

Plenary session: Adoptive Cell Therapy

8:30 - 10:00

Auditorium

- Chair: F. Marincola (USA)
 Chair: C. Bokemeyer (Germany)
- 8:30 **KEYNOTE LECTURE**
 Speaker: TBC
- 9:00 **Adoptive cell therapy with autologous tumour infiltrating lymphocytes**
 Speaker: I.M. Svane (Denmark)
- 9:20 **Autologous cellular immunotherapy for prostate cancer**
 Speaker: TBC
- 9:40 **Proffered papers**



Coffee Break

10:00 - 10:30

Foyer

Plenary session: Engineered T cell therapy

10:30 - 12:30

Auditorium

Chair: A. Shen (USA)
Chair: R. Hawkins (United Kingdom)

10:30 **KEYNOTE LECTURE: Clinical development of chimeric antigen receptors (CAR)**
Speaker: TBC

10:50 **CAR strategies in solid tumours**
Speaker: C. Rossig (Germany)

11:10 **Prolongation of T cell response by OX40 co-signalling CARs**
Speaker: H. Abken (Germany)

11:30 **Proffered papers**

End of Conference